HHC
hexahydrocannabinol
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
HHC (hexahydrocannabinol) is a semi-synthetic cannabinoid of the classical cannabinoid class. It is the fully saturated form of Δ⁹-THC — the main psychoactive compound in cannabis. It activates cannabinoid receptors in the brain, disrupting the signaling systems that regulate mood, memory, and movement.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Roger Adams first synthesized HHC in 1940 while investigating the active compounds of cannabis.[1] For eight decades it remained a laboratory tool; then in 2021, manufacturers began producing it from legal hemp-derived CBD and selling it as a THC alternative.[2] By 2024, 36 countries had reported HHC to global drug authorities, and the US assigned it Schedule I status in May 2026.[3]
Subjective effects include euphoria, sedation, altered time perception, appetite enhancement, and cognitive impairment. The experience closely resembles cannabis intoxication — a warm, settling sedation with softened senses — though variable composition in commercial products makes potency unpredictable between batches.[4][5] Anxiety, paranoia, and impaired coordination are characteristic unwanted effects.
HHC appears to have low acute toxicity,[6] but regular use is expected to carry dependence risk similar to cannabis. The defining danger is product unpredictability — commercial batches vary widely in the proportion of active compound, so identical labeled doses can produce very different effects.[5] Understanding of HHC rests almost entirely on two small pilot studies and inference from related cannabinoids.
History[edit]
Discovery
Roger Adams synthesized HHC in 1940 by fully saturating the ring structure of Δ⁹-THC, as part of early research into cannabis's active compounds.[1] A US patent for the process was filed in 1944 and granted in 1947.[7]
Research tool
For eight decades, HHC served mainly as a scientific tool for studying how cannabinoid structure affects receptor activity. The distinction between its active and weakly active forms was confirmed through molecular modeling in 1989.[8]
Market emergence and scheduling
HHC appeared on the US recreational market in late 2021, manufactured from hemp-derived CBD under the 2018 Farm Bill's hemp provisions.[2] It reached European markets by mid-2022 and became widespread across multiple jurisdictions by 2023. The WHO recommended international scheduling in October 2024,[9] and the US DEA assigned it Schedule I status in May 2026.[3]
The name "hexahydrocannabinol" reflects its relationship to THC — "hexahydro" meaning six hydrogen atoms were added to fully saturate the ring. Commercial products typically label the two forms as "alpha-HHC" (the weak form) and "beta-HHC" (the active form), though vendors apply these labels inconsistently.
Chemistry[edit]
Structural class
HHC belongs to the classical cannabinoid family — the same chemical class as Δ⁹-THC.[2] It is the fully saturated form of THC: the double bond in THC's ring is eliminated, producing a chemically more stable molecule. Molecular formula: C₂₁H₃₂O₂, molecular weight 316.5 g/mol.
Stereochemistry
This structural change creates two forms of HHC with dramatically different potency. The active (9R)-HHC engages cannabinoid receptors effectively[8] — with potency comparable to THC. The (9S)-HHC form is weakly active.[8]
Laboratory production favors the active form at roughly 7:1,[10] but commercial products vary enormously — from mostly active to mostly inactive compound.[5] HHC also occurs in trace quantities in cannabis pollen and seeds,[11] though all commercial HHC is manufactured.
Pharmacology[edit]
Mechanism of action
HHC activates cannabinoid receptors as a partial agonist. The active (9R) form is roughly 12 times more potent than the (9S) form[12] — a difference explained by how each form fits the receptor's shape.[8] The (9R) form matches Δ⁹-THC in potency. HHC favors cannabinoid receptors in the brain over those in peripheral tissue,[9] consistent with its sedating and impairing effects.
Pharmacokinetics
Two small pilot studies (3 participants each) measured HHC blood levels after 25 mg doses by inhalation and by mouth. After inhalation, peak levels appeared within about 5 minutes; after oral dosing, levels were much lower and peaked around 1 hour.[13] The overall pattern closely matches that of Δ⁹-THC.[14]
Neuroscience[edit]
Where it acts
HHC activates cannabinoid receptors concentrated in the hippocampus, amygdala, cerebellum, basal ganglia, and prefrontal cortex. As an external agonist, it overrides the brain's normal on-demand cannabinoid signaling — activating these circuits regardless of physiological need.inferred
This activation across multiple regions explains the breadth of effects: hippocampal disruption impairs memory encoding,[6] amygdala modulation shifts the experience toward relaxation or anxiety depending on dose, and cerebellar and basal ganglia effects drive motor impairment.[14][13]
Why it matters
The brain's cannabinoid system normally releases its signaling molecules only when specific neural activity demands them. HHC bypasses this precision, simultaneously activating circuits that normally operate independently. Dopamine neurons in the brain's mesolimbic pathway are disinhibited, producing euphoria and driving appetite enhancement.
No neuroimaging or electrophysiology studies specific to HHC have been conducted. Whether HHC produces the same downregulation as Δ⁹-THC with chronic use — and whether it recovers on the same 2–4 week timeline — is unknown.
Subjective Effects[edit]
The HHC experience is a conventional cannabinoid intoxication — a warm, settling heaviness that softens sensory input and slows internal tempo. Euphoria and relaxation define the easier end of the experience. The anxious and paranoid potential is also present, shaped strongly by context and individual response.
The experience closely resembles Δ⁹-THC intoxication — most users describe it as qualitatively similar but somewhat less intense.[4][5] The apparent potency gap likely reflects the weakly active (9S) epimer diluting the effect in most commercial products, rather than a fundamental difference at the receptor.
Effect Grid
Clear cannabinoid intoxication — unmistakable euphoria, noticeable sedation, and distinct time alteration. Thought deceleration becomes prominent, with ideas arriving more slowly but sometimes feeling richer or more connected. Music enhancement and humor enhancement are reliably present. Appetite enhancement is typically strong.
Physically, dry mouth is common, body high is well-established, and motor control impairment becomes noticeable — walking and fine manipulation are measurably affected. Cognitive impairment includes memory suppression and focus suppression. Anxiety is possible in sensitive individuals, particularly in unfamiliar settings.
This is the dose range where controlled studies documented measurable psychomotor impairment. Do not drive or operate machinery.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Taste enhancement · Touch enhancement · Brightness alteration · Color alteration · Depth perception distortion · Perspective distortion · Sound sensitivity · Visual haze / noise · Olfactory enhancement · Sleep-transition hallucinations · Auditory distortion · Auditory misinterpretation · Light sensitivity · Proprioceptive distortion · Vestibular distortion · Visual acuity suppression · After-images · Flashbacks · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations
Color alteration · Depth perception distortion · Perspective distortion · Sound sensitivity · Visual haze / noise · Olfactory enhancement · Sleep-transition hallucinations · Auditory distortion · Auditory misinterpretation · Light sensitivity · Proprioceptive distortion · Vestibular distortion · Visual acuity suppression · After-images · Flashbacks · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations
Body scan awareness · Heart rate perception changes · Muscle relaxation · Sedation · Bodily heaviness · Dizziness · Laughter fits · Nausea suppression · Pain suppression · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Watery eyes · Constipation · Dehydration sensation · Bodily lightness · Bodily pressures · Body schema distortion · Breathing alteration · Nausea · Nystagmus (eye wobbles) · Restlessness · Sexual arousal enhancement · Temperature dysregulation · Vomiting · Bodily dissociation
Sedation · Bodily heaviness · Dizziness · Laughter fits · Nausea suppression · Pain suppression · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Watery eyes · Constipation · Dehydration sensation · Bodily lightness · Bodily pressures · Body schema distortion · Breathing alteration · Nausea · Nystagmus (eye wobbles) · Restlessness · Sexual arousal enhancement · Vomiting · Bodily dissociation
Cognitive impairment · Focus suppression · Analysis suppression · Cognitive fatigue · Humor enhancement · Immersion enhancement · Information processing suppression · Introspection enhancement · Memory fragmentation · Novelty enhancement · Thought connectivity · Thought disorganization · Creativity enhancement · Conceptual thinking · Confusion · Delusions of sobriety · Language suppression · Motivation suppression · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought deceleration · Thought loops · Cognitive dysphoria · Thought acceleration · Amnesia · Delusions
Cognitive fatigue · Humor enhancement · Immersion enhancement · Information processing suppression · Introspection enhancement · Memory fragmentation · Novelty enhancement · Thought connectivity · Thought disorganization · Creativity enhancement · Conceptual thinking · Confusion · Language suppression · Motivation suppression · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought deceleration · Thought loops · Cognitive dysphoria · Thought acceleration · Amnesia · Delusions
Emotional lability · Dysphoria · Irritability
Disinhibition · Emotional susceptibility · Automaticity · Depersonalization · Social connection · Social disconnection · Cognitive disconnection
Social connection · Social disconnection · Cognitive disconnection
Timeline
Gradual awareness of body heaviness and a subtle mood shift. Effects may be difficult to distinguish from expectation for 30-60 minutes.
Building euphoria, emerging sedation, and the first clear perceptual changes — time begins to stretch, appetite stirs. Body high establishes.
Full cannabinoid intoxication — euphoria, sedation, time alteration, appetite enhancement, cognitive impairment, and motor control impairment are all at maximum intensity.
Gradual reduction in intensity. Sedation and body heaviness tend to persist longest while euphoria and perceptual effects recede first.
Residual sedation, mild cognitive fog, and possible lingering appetite effects. Some users report a pleasant, mellow quality.
⚠ Do not drive or operate machinery for at least 8 hours after oral HHC use — residual impairment may persist beyond subjective return to baseline.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- Δ⁹-THC · Δ⁸-THC · Other CB1 agonists
Toxicity
Acute toxicity
HHC has low acute toxicity. Animal testing found that a very large dose would be needed to cause direct toxic harm,[6] placing it in the same low-risk range as Δ⁹-THC. No human overdose case series exists for standard pentyl-chain HHC.safety citation needed
Adverse events from HHC homologs
Severe hospitalization cases in the published literature involve longer-chain relatives of HHC, not standard HHC. Two patients were hospitalized after HHC-C8 — one was unconscious for 2 days with recurring seizures, the other sedated for 3 days.[15] A separate case involving HHC-C9 caused 9 days of cognitive and physical impairment.[16] These cases reflect the higher potency of longer-chain variants and illustrate the danger of mislabeling within the HHC product family.
Product contamination
Commercial HHC products may contain unintended compounds from manufacturing: variable ratios of active compound between batches,[5] residual THC and catalyst traces,[17] and — where HHC-O is co-present — uncharacterized breakdown compounds from heating.safety citation needed
Psychological risks
At lower doses HHC tends to reduce anxiety; at higher doses it can trigger it.[6] Reports of psychotic illness triggered by HHC have emerged in Ireland,[18] though no formal case series exists, and who is most vulnerable remains uncharacterized.
Acute intoxication impairs reaction time,[6] motor coordination,[14][13] and memory. Whether these effects persist after repeated use has not been studied.
Tolerance & dependence
No HHC-specific tolerance or dependence data have been published. Based on its cannabinoid mechanism, tolerance is expected to develop within days to weeks of daily use, with cross-tolerance to Δ⁹-THC.inferred
Dependence risk comparable to cannabis is expected — approximately 9% of regular users. HHC's partial agonist nature may slightly reduce this risk.inferred
Drug interactions
No HHC-specific interaction studies exist. All interactions below are inferred from cannabinoid class pharmacology.inferred
Metabolic interactions
HHC is expected to slow liver enzymes that process many common medications,[19][20] as other cannabinoids do. This causes drug levels in the blood to rise higher and last longer than intended. Affected drugs include warfarin (increased bleeding risk), clopidogrel (reduced antiplatelet effect), anti-seizure medications, and benzodiazepines (prolonged sedation).
Pharmacodynamic interactions
- CNS depressants (alcohol, opioids, benzodiazepines, sedating antihistamines): additive sedation, motor impairment, and respiratory depression
- Other cannabinoids: additive effects; particularly relevant given residual Δ⁸/Δ⁹-THC in some products[17]
- Anticholinergics: additive dry mouth, elevated heart rate, and cognitive impairment
Contraindications
No HHC-specific contraindication studies exist. The following are inferred from cannabinoid class pharmacology.inferred
Absolute:
- Personal or family history of psychotic disorders: cannabinoid receptor activation is an established risk factor for triggering and worsening psychotic illness[18]
- Pregnancy and lactation: exogenous cannabinoid receptor activation disrupts endocannabinoid-dependent brain developmentsafety citation needed
Relative:
- Heart conditions: cannabinoid receptor agonists raise heart rate and dilate blood vesselssafety citation needed
- Anxiety disorders: dose-dependent anxiety documented in animal models[6]
- Cannabis use disorder (active or in remission): shared mechanism and expected cross-reinforcement
- Liver impairment: may prolong drug exposure and increase adverse effects
- Concurrent medications metabolized by CYP2C9/3A4: see Drug Interactions
- Adolescence: the developing brain is known to be vulnerable to cannabinoid receptor activation
Harm Reduction[edit]
Forms & Identification
HHC products present a unique identification challenge. The active and weakly active forms are chemically indistinguishable without laboratory testing, yet differ roughly 12-fold in potency. Standard reagent tests cannot differentiate HHC from Δ⁸- or Δ⁹-THC, and no field test separates the two forms.
Labeled potency on commercial HHC products is unreliable as a result. Certificates of analysis that report total HHC without specifying the ratio of active to weakly active compound provide incomplete safety information.
Guidelines
- Test a low dose from any new product or batch before committing to a full dose — epimer ratios vary unpredictably between manufacturers
- Avoid driving or operating machinery; psychomotor impairment is documented even at moderate doses[14][13]
- Oral administration has a delayed onset (1–2 hours); wait the full onset window before redosing
- Have food and water accessible — appetite enhancement and dry mouth are common
- If prone to anxiety or panic, start very low and use only in a comfortable setting with a trusted person present
Set & Setting
HHC's tendency to shift from relaxing to anxiety-inducing makes environment particularly important. Calm, familiar settings with trusted companions reduce the likelihood of paranoid or anxious responses. Crowded or high-stimulation environments amplify the anxiogenic potential at moderate to high doses.
Treat each new product or batch as an unknown quantity. Prior experience with one brand does not reliably predict the intensity of another, because the ratio of active compound varies between manufacturers.
Aftercare & integration. HHC's cognitive effects — including memory disruption and mental fog — may persist for several hours after the main experience ends. Plan for a recovery window: avoid demanding tasks, drive only after full clarity returns, and allow extra sleep if needed.
Hydration and light food help counter dry mouth and appetite disruption during the tail end of effects. If anxiety or paranoia were prominent during the experience, slow breathing, physical contact with a familiar object, or steady reassurance from a companion can help restore baseline.
Recovery & Support
Regular HHC use carries dependence risk comparable to cannabis. Signs of problematic use include escalating doses, using to manage anxiety or sleep despite worsening baseline function, and difficulty stopping despite wanting to.
Cannabis-specific support resources apply: Marijuana Anonymous (ma-online.org), SMART Recovery, and local substance use counseling. A healthcare provider familiar with cannabinoid dependence can help develop a tapering strategy if abrupt cessation proves difficult.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Most uncomfortable HHC experiences resolve with time and reassurance. Seek immediate help if any of the following occur: chest pain or irregular heartbeat, seizures, loss of consciousness, severe confusion or psychotic symptoms, or prolonged vomiting.
- Call emergency services immediately if the person is unresponsive, seizing, or expressing intent to harm themselves
- Place an unconscious but breathing person in the recovery position (on their side)
- Do not leave the person alone
- Do not induce vomiting
- Keep the environment calm, reduce stimulation, and speak in a steady voice
Tell the dispatcher: what was taken (HHC), approximate amount and time, route of administration (vaped or eaten), and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
HHC is now internationally controlled, following a 2024 WHO recommendation and a wave of national prohibitions that accelerated after 2022.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Drug code 7220 assigned May 4, 2026[3] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Production, supply, and import for human consumption are illegal |
| France | Banned | Among first EU member states to prohibit HHC (2023) |
| Germany | Controlled (Narcotics Act) | Added to controlled substances list in 2023 |
| Austria | Controlled | Added to controlled substances in 2023 |
| Poland | Controlled | Effective April 14, 2023 |
| Sweden | Classified as narcotic | HHC and HHCP scheduled simultaneously, effective July 11, 2023[21] |
| Ireland | Controlled | HHC sold openly until July 2025; subsequently controlled[18] |
| International (UN) | Schedule II, 1971 Convention on Psychotropic Substances | WHO ECDD recommendation (October 2024) ratified March 2025[9] |
| Canada | Not confirmed | No specific scheduling information verifiedcitation needed |
| Australia | Not confirmed | No specific scheduling information verifiedcitation needed |
Legal status changes frequently. The information above reflects the state of the law as of early 2026 and is not legal advice. Verify local regulations before possessing, producing, or supplying HHC.
references
- [1]
- [2] ^abcUjváry I (2024) Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review — Drug Testing and Analysis doi:10.1002/dta.3519
- [3]
- [4] ^abCaprari C, Ferri E, Vandelli MA, Citti C, Cannazza G (2024) An emerging trend in Novel Psychoactive Substances (NPSs): designer THC — Journal of Cannabis Research doi:10.1186/s42238-024-00226-y
- [5]
- [6]